Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2022 02:30 ET | Source: Novartis Pharma AG

Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and...
September 09, 2022 01:15 ET | Source: Novartis Pharma AG

Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer

New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with...
September 02, 2022 01:15 ET | Source: Novartis Pharma AG

Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses

Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of...
September 01, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis

After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr....
August 30, 2022 01:15 ET | Source: Novartis Pharma AG

Novartis presents new data in breast and prostate cancer at ESMO

Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali® Data from VISION study reporting...
August 25, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off

Ad hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1...
August 25, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten

Ad-hoc-Mitteilung gemäss Art. 53 KR Die strategische Überprüfung von Sandoz hat ergeben, dass eine Abspaltung von Sandoz durch eine hundertprozentige Ausgliederung im besten Interesse der...
August 15, 2022 01:15 ET | Source: Novartis Pharma AG

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer

Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be presented at...
July 25, 2022 01:15 ET | Source: Novartis Pharma AG

Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EUMultiple sclerosis (MS) is a chronic inflammatory...
July 21, 2022 01:15 ET | Source: Novartis Pharma AG

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)

Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic...